CX3CR1 and amyotrophic lateral sclerosis: Recently, loss-of-function variants in the microglial fractalkine receptor (CX3CR1) have been associated with worsened Braak staging in AD and neurodegeneration along with reduced survival in amyotrophic lateral sclerosis (ALS), implicating these SNPs as disease-modifying variants in neurodegenerative diseases [6–8].